Iovance Biotherapeutics reports Q3 revenue of $121.5 million
Iovance reported Q3 revenue of $121.5 million, versus a FactSet estimate of $116.0 million.
Related stories
Lightspeed Commerce Reports Second-Quarter Loss per Share
M impact | EQUITY | Nov 05, 2026, 12:22 PM UTC
Evolent Health Reports Third-Quarter Revenue of $725.37 Million
Revenue rose 51.3% year over year as the net loss narrowed. Growth reflected Performance Suite contract go-lives and expanded oncology services, partly offset by lower membership a
M impact | EQUITY | Nov 05, 2026, 12:19 PM UTC
Iovance Reports Third-Quarter 2026 Revenue of About $122 Million
Iovance said total revenue increased about 80% year over year and U.S. Amtagvi revenue rose about 77%.
M impact | EQUITY | Nov 05, 2026, 12:19 PM UTC
Illumin Holdings reports third-quarter loss of C$0.03 per share
M impact | EQUITY | Nov 05, 2026, 12:14 PM UTC
Commerce Reports Third-Quarter 2026 Revenue of $84.25M, EPS Loss of $0.04
Revenue declined year over year as lower partner and services revenue more than offset slightly higher subscription solutions revenue. The company reported a wider net loss.
M impact | EQUITY | Nov 05, 2026, 12:14 PM UTC
Molson Coors Reports Q3 Earnings, Lowered 2026 Outlook
Molson Coors reported Q3 non-GAAP earnings; net sales fell and the company lowered its 2026 outlook.
M impact | EQUITY | Nov 05, 2026, 12:14 PM UTC